Watching alerts...
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
New study: My Experiences: Leveraging Digital Technologies to Better Understand Mental Health
MindMed listed as collaborator.
Sponsored by 4YouandMe
https://clinicaltrials.gov/ct2/show/NCT05753605
Brief Summary:
Mental health disorders are one of the most challenging chronic conditions to identify, treat and manage. This is largely due to the fact that diagnoses are almost entirely based on the patient's recall of current and past subjective experiences of symptoms; and then further interpreted by a healthcare professional introducing multiple layers of information biases in the formulation of a diagnosis. Accordingly, mental health conditions remain prevalent with high rates of misdiagnosis, inappropriate treatment and delayed intervention. In light of the heterogeneity across and within mental health conditions, a personalized interventional approach holds merit, yet the tools to effectively track an individual's day to day objective and subjective experience needed to achieve an individualized care approach have not until recently existed.
Digital technologies such as passive and active sensing from smartphones and from wearable devices are shedding light on the capabilities of tracking new objective measures of health that could translate to key symptoms of mental health conditions. 'Multimodal data' approaches are those that attempt to translate a variety of electrical signals from digital devices to relevant health outcomes. The combination of digital devices to detect multimodal measures of mental health symptoms offers a unique opportunity to take a ground up approach in understanding the fluidity of mental health symptoms occurring at the individual level that might lend insight into new phenotypes of mental health illnesses that could have a physiological underpinning.
The Study Investigators aim to characterize the multiplexing and fluid nature of mental health symptoms across individuals experiencing mental health symptoms and conditions using digital tools (i.e., wearables and mobile apps) and additional context information collected from virtual study support calls.
The Investigators hope to know how objective measures from sensor data translate to core symptoms, episodes and flares across mental health disorders, and develop new (or new applications of) machine learning anomaly detection approaches and determine whether anomalies in expected symptom portraits can be reliably detected and enhanced by the addition of objectively measured data.
MindMed Appoints Mark R. Sullivan as Chief Legal Officer and Corporate Secretary
April 13, 2023 07:00 AM Eastern Daylight Time
https://www.businesswire.com/news/home/20230413005290/en/MindMed-Appoints-Mark-R.-Sullivan-as-Chief-Legal-Officer-and-Corporate-Secretary
NEW YORK--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the “Company” or "MindMed"), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the appointment of Mark R. Sullivan, effective today, as Chief Legal Officer and Corporate Secretary.
“I look forward to working with the MindMed management team as the Company continues advancing its clinical programs and pursues commercial capabilities to fulfill its mission of improving the lives of the millions of individuals suffering from brain health disorders.”
Tweet this
“We are very excited to welcome Mark to our management team. Mark brings tremendous legal and public company life sciences expertise and will be a strong addition to our executive team. We believe Mark’s experience, insights and guidance will prove invaluable as MindMed progresses to the next stage of its evolution. I look forward to working closely with Mark during this transformative time for the company,” said Robert Barrow, Chief Executive Officer and Director of MindMed.
“This is an exciting time to be joining the Company at this pivotal juncture as it advances towards several key inflection points for its pipeline,” said Mr. Sullivan. “I look forward to working with the MindMed management team as the Company continues advancing its clinical programs and pursues commercial capabilities to fulfill its mission of improving the lives of the millions of individuals suffering from brain health disorders.”
Mr. Sullivan is an experienced public company General Counsel and Corporate Secretary, with extensive expertise and demonstrated success in the areas of SEC reporting, financing, corporate governance and compliance, mergers and acquisitions, intellectual property, litigation management and business development. Prior to joining the Company, Mr. Sullivan was the General Counsel and Corporate Secretary of Sesen Bio, a biopharmaceutical company (prior to its merger with Carisma Therapeutics) (NASDAQ: CARM), from August 2019 to April 2023. Before that, he served as a private consultant to numerous life sciences companies. Previously, he served as the General Counsel, Chief Compliance Officer and Secretary of MModal Inc. (Nasdaq: MODL), formerly MedQuist, Inc., a leading healthcare IT company, until it was taken private by One Equity Partners, the private investment arm of JP Morgan Chase & Co. Prior to joining MModal, Mr. Sullivan was in private practice with Pepper Hamilton LLP and Drinker Biddle & Reath LLP. Mr. Sullivan received a B.A. from the University of Pennsylvania and a J.D. from the Rutgers University School of Law.
About MindMed
MindMed is a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders. Our mission is to be the global leader in the development and delivery of treatments that unlock new opportunities to improve patient outcomes. We are developing a pipeline of innovative product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways that play key roles in brain health disorders.
MindMed trades on NASDAQ under the symbol MNMD and on the Canadian NEO Exchange under the symbol MMED.
Forward-Looking Statements
Certain statements in this news release related to the Company constitute “forward-looking information” within the meaning of applicable securities laws and are prospective in nature. Forward-looking information is not based on historical facts, but rather on current expectations and projections about future events and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements. These statements generally can be identified by the use of forward-looking words such as “will”, “may”, “should”, “could”, “intend”, “estimate”, “plan”, “anticipate”, “expect”, “believe”, “potential” or “continue”, or the negative thereof or similar variations. Forward-looking information in this news release includes, but is not limited to, statements regarding anticipated upcoming milestones, trials and studies, results and timing of clinical trials. There are numerous risks and uncertainties that could cause actual results and the Company’s plans and objectives to differ materially from those expressed in the forward-looking information, including history of negative cash flows; limited operating history; incurrence of future losses; availability of additional capital; lack of product revenue; compliance with laws and regulations; difficulty associated with research and development; risks associated with clinical trials or studies; heightened regulatory scrutiny; early stage product development; clinical trial risks; regulatory approval processes; novelty of the psychedelic inspired medicines industry; as well as those risk factors discussed or referred to herein and the risks described in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2022 under headings such as “Special Note Regarding Forward-Looking Statements,” and “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and other filings and furnishings made by the Company with the securities regulatory authorities in all provinces and territories of Canada which are available under the Company’s profile on SEDAR at www.sedar.com and with the U.S. Securities and Exchange Commission on EDGAR at www.sec.gov. Except as required by law, the Company undertakes no duty or obligation to update any forward-looking statements contained in this release as a result of new information, future events, changes in expectations or otherwise.
Contacts
For Media & Investor Inquiries, please contact:
Maxim Jacobs, CFA
Vice President, Investor Relations and Corporate Communications
Mind Medicine (MindMed) Inc.
ir@mindmed.co
media@mindmed.co
Damn! I meant to get more... this is going to start moving now. Nice interview!
This is why I won't blast until direction... is a slug until then
All the chatter will get this flying.
Easter bunny first then Dubs
Thanks for posting
Money for miles on this one once we get moving.
I will only ask blast when a PR comes... this one I WILL chase because it is on watch. However, I do not trust the captain so I will wait for the wave to start. Then surf...
Can't wait for that copper because its coming.
I smell a few more PRs coming next week :)
Chart looking nice!
Interesting. We are going to pop soon.
Unreal how nice this one holds up. I see .50 coming over the next month!
It will be fun
Well again... I hate to say I told anyone so, BUT.... I will jump back in when PRs start again, but until then this will continue as normal.
Time to get this party started I see
Nice... PRs to follow
Don't think so... 86,856,772 float is pretty low and it trades thin.. even it is does it will drop. maybe .02 and then shoot up. Very thin here.
It is curious that this is not trading today... At least I see no volume. Anyone else?
I'm ready when they are...
Looking forward to get rocking and rolling!
You aren't getting my shares :)
acquisition completed
Let's see if Ken sends a balloon out with a PR attached soon.
Good morning STEV group. What do you say we get this party started again? :)
I see this going higher than where it currently is. I see a better rush when we get more news.
I know this one too well. But now is a good time to get in but a lot of people hung on for the slide down. There's only so much you can do when you lead horses to water.
I really just have to wait for a confirmed run.
Are we saying it's time to make money again :P.... ready when the PRs are. As panzer says... I'll brink the ask slapping units!
When Ken's ready....
2.9M slap
I will agree with you on that...
Company should be updating us with more information soon.
Working on it.
I guess we will have to dig and see what we can find out.
TD Ameritrade will allow you to purchase as well. You just call them up to activate OTC purchases. That's what I use to buy.
Angermayer bought directly from Cathie Woods (+1.2M shares)
Share buyback...
https://atai.gcs-web.com/static-files/3fd4ef21-896f-4141-bdad-e9b205531809
You are in at the right time.
There is just so much fucking red on the volume transactions though. Is it me?